Portal de Periódicos da CAPES

Do Anxiety and Distress Increase During Active Surveillance for Low Risk Prostate Cancer?

2010; Lippincott Williams & Wilkins; Volume: 183; Issue: 5 Linguagem: Inglês

10.1016/j.juro.2009.12.099

1527-3792

Roderick C.N. van den Bergh, Marie‐Louise Essink‐Bot, Monique J. Roobol, Fritz H. Schröder, Chris H. Bangma, Ewout W. Steyerberg,

Prostate Cancer Diagnosis and Treatment

No AccessJournal of UrologyAdult Urology1 May 2010Do Anxiety and Distress Increase During Active Surveillance for Low Risk Prostate Cancer? Roderick C.N. van den Bergh, Marie-Louise Essink-Bot, Monique J. Roobol, Fritz H. Schröder, Chris H. Bangma, and Ewout W. Steyerberg Roderick C.N. van den BerghRoderick C.N. van den Bergh Erasmus Medical Center, Rotterdam, The Netherlands , Marie-Louise Essink-BotMarie-Louise Essink-Bot Department of Public Health, Erasmus Medical Center, Rotterdam, The Netherlands Institute of Social Medicine, Academic Medical Centre, Amsterdam, The Netherlands , Monique J. RoobolMonique J. Roobol Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands , Fritz H. SchröderFritz H. Schröder Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands , Chris H. BangmaChris H. Bangma Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands , and Ewout W. SteyerbergEwout W. Steyerberg Department of Public Health, Erasmus Medical Center, Rotterdam, The Netherlands View All Author Informationhttps://doi.org/10.1016/j.juro.2009.12.099AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Anxiety and distress may be present in patients with low risk prostate cancer who are on active surveillance. This may be a reason to discontinue active surveillance. Materials and Methods: A total of 150 Dutch patients with prostate cancer on active surveillance in a prospective active surveillance study received questionnaires at study inclusion and 9 months after diagnosis. We assessed changes in scores on decisional conflict with the decisional conflict scale, depression with the Center for Epidemiologic Studies Depression Scale, generic anxiety with the State Trait Anxiety Inventory, prostate cancer specific anxiety with the Memorial Anxiety Scale for Prostate Cancer and the self-estimated risk of progression. We explored scores 9 months after diagnosis vs those at study inclusion for physical health (SF-12® physical component summary), personality (Eysenck Personality Questionnaire), shared decision making, prostate cancer knowledge, demographics, medical parameters and prostate specific antigen doubling time during followup. Results: Questionnaires at study inclusion and 9 months after diagnosis were completed by 129 of 150 (86%) and 108 of 120 participants (90%) a median of 2.4 and 9.2 months after diagnosis, respectively. Anxiety and distress at study inclusion were previously found to be generally favorable. Significant but clinically irrelevant decreases were seen in mean scores of the State Trait Anxiety Inventory (p = 0.016), Memorial Anxiety Scale for Prostate Cancer fear of progression subscale (p = 0.005) and the self-estimated risk of progression (p = 0.049). Anxiety and distress 9 months after diagnosis were mainly predicted by scores at study inclusion. Higher Eysenck Personality Questionnaire neuroticism score and an important role of the physician in the treatment decision had additionally unfavorable effects. Good physical health, palpable disease and older age had favorable effects. No association was seen for prostate specific antigen doubling time. Nine men discontinued active surveillance, including 2 due to nonmedical reasons. Conclusions: Anxiety and distress generally remain favorably low during the first 9 months of surveillance. References 1 : Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol2004; 5: 101. Google Scholar 2 : Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol2007; 178: S14. Link, Google Scholar 3 : Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol2009; 55: 1. Google Scholar 4 : Anxiety and distress during active surveillance for early prostate cancer. Cancer2009; 115: 3868. Google Scholar 5 : Uncertainty and quality of life of older men who undergo watchful waiting for prostate cancer. Oncol Nurs Forum2003; 30: 303. Google Scholar 6 : Patients' perceptions of quality of life after treatment for early prostate cancer. J Clin Oncol2003; 21: 3777. Google Scholar 7 : The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol2007; 178: 826. Link, Google Scholar 8 : Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol2007; 52: 1560. Google Scholar 9 : Validation of a decisional conflict scale. Med Decis Making1995; 15: 25. Google Scholar 10 : The Center for Epidemiologic Studies Depression Scale: its use in a community sample. Am J Psychiatry1983; 140: 41. Google Scholar 11 : The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol1992; 31: 301. Google Scholar 12 : The Memorial Anxiety Scale for Prostate Cancer: validation of a new scale to measure anxiety in men with prostate cancer. Cancer2003; 97: 2910. Google Scholar 13 : A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care1996; 34: 220. Google Scholar 14 : Manual of the Eysenck Personality Scales (EPS Adult). London: Hodder & Stoughton1991. Google Scholar 15 : A screening tool for depression in the elderly in the general population: the usefulness of Center for Epidemiological Studies Depression Scale (CES-D). Tijdschr Gerontol Geriatr1994; 25: 95. Google Scholar 16 : The decisional conflict scale: further validation in two samples of Dutch oncology patients. Patient Educ Couns2001; 45: 187. Google Scholar 17 : Testing Dutch and French translations of the SF-36 Health Survey among Belgian angina patients. J Clin Epidemiol1998; 51: 975. Google Scholar 18 : Het meten van persoonlijkheidskenmerken met de Eysenck Personality Questionnaire (EPQ): een handleiding: Noordelijk centrum voor gezondheidsvraagstukken. Groningen, The Netherlands: Rijksuniversiteit Groningen1995. Google Scholar 19 : Prostate cancer-specific anxiety in Dutch patients on active surveillance: validation of the Memorial Anxiety Scale for Prostate Cancer. Qual Life Res2009; 18: 1061. Google Scholar 20 : Validation of the Dutch short form of the state scale of the Spielberger State-Trait Anxiety Inventory: considerations for usage in screening outcomes. Commun Genet2003; 6: 84. Google Scholar 21 : Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care2003; 41: 582. Google Scholar 22 : Prediction of outcome in patients presenting with fatigue in primary care. Br J Gen Pract2009; 59: e101. Google Scholar 23 : Is 'watchful waiting' a real choice for men with prostate cancer?: A qualitative study. BJU Int2002; 90: 257. Google Scholar 24 : Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. BJU Int2007; 100: 544. Google Scholar 25 : Does active surveillance for men with localized prostate cancer carry psychological morbidity?. BJU Int2007; 100: 540. Google Scholar 26 : After prostate cancer: predictors of well-being among long-term prostate cancer survivors. Cancer2006; 106: 2128. Google Scholar 27 : Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer2005; 116: 291. Google Scholar 28 : Screening and prostate-cancer mortality in a randomized European study. N Engl J Med2009; 360: 1320. Google Scholar 29 : Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess2003; 7: 1. Google Scholar © 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byHalstuch D, Ber Y, Kedar D, Golan S, Baniel J and Margel D (2020) Short-Term Outcomes of Active Surveillance for Low Risk Prostate Cancer among Men with Germline DNA Repair Gene MutationsJournal of Urology, VOL. 204, NO. 4, (707-713), Online publication date: 1-Oct-2020.Marzouk K, Assel M, Ehdaie B and Vickers A (2018) Long-Term Cancer Specific Anxiety in Men Undergoing Active Surveillance of Prostate Cancer: Findings from a Large Prospective CohortJournal of Urology, VOL. 200, NO. 6, (1250-1255), Online publication date: 1-Dec-2018.Taneja S (2017) Re: Treatment Decision Regret among Long-Term Survivors of Localized Prostate Cancer: Results from the Prostate Cancer Outcomes StudyJournal of Urology, VOL. 198, NO. 5, (980-983), Online publication date: 1-Nov-2017.Kovac E, Lieser G, Elshafei A, Jones J, Klein E and Stephenson A (2016) Outcomes of Active Surveillance after Initial Surveillance Prostate BiopsyJournal of Urology, VOL. 197, NO. 1, (84-89), Online publication date: 1-Jan-2017. Volume 183Issue 5May 2010Page: 1786-1791 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.Keywordsanxietyprostateprostatic neoplasmsquestionnairesquality of lifeMetricsAuthor Information Roderick C.N. van den Bergh Erasmus Medical Center, Rotterdam, The Netherlands More articles by this author Marie-Louise Essink-Bot Department of Public Health, Erasmus Medical Center, Rotterdam, The Netherlands Institute of Social Medicine, Academic Medical Centre, Amsterdam, The Netherlands More articles by this author Monique J. Roobol Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands More articles by this author Fritz H. Schröder Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands More articles by this author Chris H. Bangma Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands More articles by this author Ewout W. Steyerberg Department of Public Health, Erasmus Medical Center, Rotterdam, The Netherlands More articles by this author Expand All Advertisement PDF downloadLoading ...